Journal of Endocrinological Investigation

, Volume 26, Issue 12, pp 1219–1224 | Cite as

Serum leptin levels in acromegalic patients before and during somatostatin analogs therapy

  • R. Baldelli
  • C. Durante
  • E. D’Amico
  • F. Diacono
  • G. Tamburrano
  • F. F. Casanueva
Original Article


GH excess is characterized by alterations of body composition such as decreased body fat mass; however, scant data are present regarding its effect on serum leptin levels. To better elucidate this topic, leptin secretion was studied in 20 acromegalic patients, before and after 6 months of treatment with somatostatin analogs (SR-lanreotide 30 mg and octreotide LAR). Basal GH, IGF-I, insulin, blood glucose and lipid levels were measured and the area under the curve (AUC) for insulin and glucose and oral glucose insulin sensitivity (OGIS) during oral glucose tolerance test (OGTT) were calculated. After 6 months of somatostatin analogs therapy, a significant reduction in GH and IGF-I plasma levels was observed (p<0.0005, both) with a significant increase of leptin levels (7.4±1.3 vs 13.2±1.6 ng/ml; p<0.05). Interestingly, the typical correlation of leptin with body mass index (BMI) was not present in active acromegaly, whereas it was restored after somatostatin analogs treatment; moreover, the gender difference in leptin secretion between men and women was preserved in active and controlled acromegaly. In conclusion, the gender-based leptin differences are preserved and leptin secretion/BMI ratio is normalized in acromegalic patients after somatostatin analogs therapy.


acromegaly SR-Lanreotide octreotide-LAR leptin insulin GH IGF-I 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman J.M. Positional cloning of the mouse obese gene and its human homologue. Nature 1994, 372: 425–32.PubMedCrossRefGoogle Scholar
  2. 2.
    Pelleymounter MA, Cullen MJ, Baker MB, et al. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 1995, 269: 540–3.PubMedCrossRefGoogle Scholar
  3. 3.
    Halaas JL, Gajiwala KS, Maffei M, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995, 269: 543–6.PubMedCrossRefGoogle Scholar
  4. 4.
    Campfield L, Smith F, Guisez Y, Devos R, Burn P. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science 1995, 269: 546–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Considine RV, Considine EL, Williams CJ, Hyde TM, Caro JF. The hypothalamic leptin receptor in humans: identification of incidental sequence polymorphisms and absence of the db/db mouse and fa/fa rat mutations. Diabetes 1996, 45: 992–4.PubMedCrossRefGoogle Scholar
  6. 6.
    Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996, 334: 292–5.PubMedCrossRefGoogle Scholar
  7. 7.
    Considine RV, Nyce MR, Kolaczynski JW, et al. Dexamethasone stimulates leptin release from human adipocytes: unexpected inhibition by insulin. J Cell Biochem 1997, 65: 254–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Menendez C, Baldelli R, Lage M, et al. The in vitro leptin secretion of human leptin is gender-dependent but independent of the body mass index of the donors. Eur J Endocrinol 2000, 143: 711–4.PubMedCrossRefGoogle Scholar
  9. 9.
    Hamilton BS, Paglia D, Kwan AY, Deitel M. Increased obese mRNA expression in omental fat cells from massively obese humans. Nat Med 1995, 1: 953–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Montague CT, Prins JB, Sanders L, Digby JE, O’Rahilly S. Depot- and sex-specific differences in human leptin mRNA expression: implications for the control of regional fat distribution. Diabetes 1997, 46: 342–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Leal-Cerro A, Considine RV, Peino R, Venegas E, Astorga R, Casanueva FF. Serum immunoreactive-leptin levels are increased in patients with Cushing’s syndrome. Horm Metab Res 1996, 28: 711–3.PubMedCrossRefGoogle Scholar
  12. 12.
    Casabiell X, Piñeiro V, Cruz L. Dual effect of insulin on in vitro leptin secretion by adipose tissue. Biochem Biophys Res Comm 2000, 276: 477–82.PubMedCrossRefGoogle Scholar
  13. 13.
    Piñeiro V, Casabiell X, Peinó R, et al. Dihydrotestosterone, stanazol, androstenedione and dehydroepiandrosterone sulphate inhibit leptin secretion in female but not in male samples of omental adipose tissue in vitro: lack of effect of testosterone. J Endocrinol 1999, 160: 425–32.PubMedCrossRefGoogle Scholar
  14. 14.
    Miyakawa M, Tsushima T, Murakami H, Isozaki O, Demura H, Tanaka T. Effect of growth hormone (GH) on serum concentrations of leptin: study in patients with acromegaly and GH deficiency. J Clin Endocrinol Metab 1998, 83: 3476–9.PubMedGoogle Scholar
  15. 15.
    Janssen YJH, Frölich M, Deurenberg P, Roelfsema F. Serum leptin levels during recombinant human GH therapy in adults with GH deficiency. Eur J Endocrinol (Oxf) 1997, 137: 650–4.CrossRefGoogle Scholar
  16. 16.
    Nystrom F, Ekman B, Österlund M, Lindström T, Öhman KP, Arnqvist HJ. Serum leptin concentrations in normal population and GH deficiency: negative correlation with testosterone in men and effects of GH treatment. Clin Endocrinol (Oxf) 1997, 47: 191–8.CrossRefGoogle Scholar
  17. 17.
    Bianda TL, Glatz Y, Boeni-Schnetzler M, Froesch ER, Schmid C. Effects of growth hormone (GH) and insulin-like growth factor-I on serum leptin in GH-deficient adults. Diabetologia 1997, 40: 363–4.PubMedGoogle Scholar
  18. 18.
    Bengtsson BA, Brummer R-JM, Eden S, Bosaeus I. Body composition in acromegaly. Clin Endocrinol 1989, 30: 121–30.CrossRefGoogle Scholar
  19. 19.
    Damjanovic S, Petakov S, Raicevic S, et al. Serum leptin levels in patients with acromegaly before and after correction of hypersomatotropism by trans-sphenoidal surgery. J Clin Endocrinol Metab 2000, 85: 147–54.PubMedCrossRefGoogle Scholar
  20. 20.
    Al-Maskari M, Gebbie J, Kendall-Taylor P. The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly. Clin Endocrinol (Oxf) 1996, 45: 415–21.CrossRefGoogle Scholar
  21. 21.
    Caron P, Morange-Ramos I, Cogne M, Jaquet P. Three years follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab 1997, 82: 18–22.PubMedGoogle Scholar
  22. 22.
    Fløgstad AK, Halse J, Bakke S, et al. Sandostatin LAR in acromegalic patients: long-term treatment. J Clin Endocrinol Metab 1997, 82: 23–28.PubMedCrossRefGoogle Scholar
  23. 23.
    Baldelli R, Colao A, Razzore P, et al. Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg). J Clin Endocrinol Metab 2000, 85: 4099–103.PubMedGoogle Scholar
  24. 24.
    Baldelli R, Dieguez C, Casanueva FF. Acromegaly: from basic research to clinical studies. Pol J Endocrinol 2001, 52: 57–79.Google Scholar
  25. 25.
    Bolanowski M, Milewicz A, Bidzinska B, Jedrzejuk D, Daroszewski J, Mikulski E. Serum leptin levels in acromegaly: a significant role for adipose tissue and fasting insulin/glucose ratio. Med Sci Monit 2002, 8: 685–9.Google Scholar
  26. 26.
    Tan KC, Tso AW, Lam KS. Effect of Sandostatin LAR on serum leptin levels in patients with acromegaly. Clin Endocrinol (Oxf) 2001, 54: 31–5.CrossRefGoogle Scholar
  27. 27.
    Giustina A, Barkan A. Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000, 85: 526–9.PubMedGoogle Scholar
  28. 28.
    Clayton RN. New developments in the management of acromegaly. Should we achieve absolute biochemical cure? J Endocrinol 1997, 155: 23–9.Google Scholar
  29. 29.
    Colao A, Lombardi G. Growth hormone excess and PRL excess. Lancet 1999, 352: 1455–61.CrossRefGoogle Scholar
  30. 30.
    The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diab Care 1997, 20: 1183–97.Google Scholar
  31. 31.
    Mari A, Pacini G, Murphy E, et al. A model-based for assessing insulin sensitivity from the oral glucose tolerance test. Diab Care 2001 24: 539–48.CrossRefGoogle Scholar
  32. 32.
    Goedman HG. Growth hormone and the metabolism of carbohydrate and lipid in adipose tissue. Ann N Y Acad Sci 1968, 148: 419–22.CrossRefGoogle Scholar
  33. 33.
    Kolaczynski JW, Nyce MR, Considine RV, et al. Acute and chronic effects of insulin on leptin production in humans: studies in vivo and in vitro. Diabetes 1996, 45: 699–701.PubMedCrossRefGoogle Scholar
  34. 34.
    Rosenbaum M, Nicolson M, Hirsch J, et al. Effects of gender, body composition, and menopause on plasma concentrations of leptin. J Clin Endocrinol Metab 1996, 81: 3424–7.PubMedGoogle Scholar
  35. 35.
    Salamon F, Cuneo RC, Hesp R, Sönksen PH. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 1989, 321: 1797–803.CrossRefGoogle Scholar
  36. 36.
    Gill MS, Toogood AA, O’Neill PA, et al. Relationship between growth hormone (GH) status, serum leptin and body composition in healthy and GH deficient elderly subjects. Clin Endocrinol (Oxf) 1997, 47: 161–7.CrossRefGoogle Scholar
  37. 37.
    Malmstrom R, Taskinen M-R, Karonen S-L, Yki-Jarvinen H. Insulin increases plasma leptin in normal subjects and patients with NIDDM. Diabetologia 1996, 39: 993–6.PubMedCrossRefGoogle Scholar
  38. 38.
    Dagogo-Jack S, Fanelli C, Paramore D, Brothers J, Landt M. Plasma leptin and insulin relationship in obese and nonobese humans. Diabetes 1996, 45: 695–8.PubMedCrossRefGoogle Scholar
  39. 39.
    Vidal H, Aubouef D, DeVos P, et al. The expression of ob gene is not acutely regulated by insulin and fasting in human abdominal subcutaneous adipose tissue. J Clin Invest 1996, 98: 251–5.PubMedCentralPubMedCrossRefGoogle Scholar
  40. 40.
    Pratley RE, Nicolson M, Bogardus C, Ravussin E. Effects of acute hyperinsulinemia on plasma leptin concentrations in insulin-sensitive and insulin-resistant Pima Indians. J Clin Endocrinol Metab 1996, 81: 4418–21.PubMedGoogle Scholar
  41. 41.
    Ryan AS, Elahi D. The effects of acute hyperglicaemia and hyperinsulinaemia on plasma leptin levels: its relationships with body fat, visceral adiposity, and age in women. J Clin Endocrinol Metab 1996, 81: 4433–8.PubMedGoogle Scholar
  42. 42.
    Utriainen T, Malmstrom R, Makimattila S, Yki-Jarvinen H. Supraphysiological hyperinsulinaemia increases plasma leptin concentrations after 4 h in normal subjects. Diabetes 1996, 45: 1364–6.PubMedCrossRefGoogle Scholar
  43. 43.
    Popovic V, Micic D, Damjanovic S, et al. Serum leptin and insulin concentrations in patients with insulinoma before and after surgery. Eur J Endocrinol 1998, 138: 86–8.PubMedCrossRefGoogle Scholar
  44. 44.
    D’Adamo M, Buongiorno A, Maroccia E, et al. Increased OB gene expression leads to elevated plasma leptin concentrations in patients wit chronic primary hyperinsulinemia. Diabetes 1998, 47: 1625–9.PubMedCrossRefGoogle Scholar
  45. 45.
    Baldelli R, Battista C, Leonetti F, et al. Glucose homeostasis in acromegaly: effects of long acting somatostatin analogs treatment. Clin Endocrinol (Oxf) 2003, 59: 492–9.CrossRefGoogle Scholar
  46. 46.
    Foss MC, Saad JA. Paccola GM, Paula JA, Piccinato CE, Moreira AC. Peripheal Glucose Metabolism in Acromegaly. J Clin Endocrinol Metab 1991, 72: 1048–53.PubMedCrossRefGoogle Scholar
  47. 47.
    Gama R, Teale JD, Wright J, Ferns G, Marks V. Hyperproinsulinaemia in acromegaly: evidence for abnormal pancreatic beta-cell function. Ann Clin Biochem 1997, 34: 627–31.PubMedCrossRefGoogle Scholar
  48. 48.
    Muggeo M, Robert S. Bar, Roth J, Kahn R. The insulin resistance of acromegaly: evidence for two alterations in the insulin receptor on circulating monocytes. J Clin Endocrinol Metab 1979, 48: 17–24.PubMedCrossRefGoogle Scholar
  49. 49.
    Hansen I, Tsalikian E, Beaufrere B, Gerich J, Haymond M, Rizza R. Insulin resistance in acromegaly: defects in both hepatic and extrahepatic insulin action. Am J Physiol 1986, 250: 269–73.Google Scholar
  50. 50.
    Flier JS. Leptin expression and action: new experimental paradigms. Proc Nat Acad Sci 1997, 94: 4242–5.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2003

Authors and Affiliations

  • R. Baldelli
    • 1
    • 2
  • C. Durante
    • 1
  • E. D’Amico
    • 1
  • F. Diacono
    • 1
  • G. Tamburrano
    • 1
  • F. F. Casanueva
    • 2
  1. 1.Department of Clinical Sciences, Endocrinology Section, First School of MedicineUniversity of Rome “La Sapienza”RomeItaly
  2. 2.Molecular Endocrinology Section, Department of MedicineUniversity of Santiago de CompostelaSpainItaly

Personalised recommendations